IL-2 immunotherapy in chronically SIV-infected Rhesus macaques

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• Interleukin-2 (IL-2) therapy increases CD4+ T cells in HIV patients but lacks clinical benefit.
• Hypotheses for this discrepancy remain unexplored.
• This study examines IL-2 dosage effects in SIV-infected Rhesus macaques without antiretroviral therapy (ART).

Purpose of the Study:

• To investigate the impact of low and high doses of recombinant IL-2 (rIL-2) on SIV-infected Rhesus macaques.
• To understand the dose-dependent effects of IL-2 on T cell populations and viral load.
• To elucidate the mechanisms behind IL-2's clinical outcomes in the context of SIV/HIV infection.

Main Methods:

• Administered low and high doses of rIL-2 to SIVmac251-infected Rhesus macaques.
• Monitored CD4+ and CD8+ T cell counts, regulatory T cells (Tregs), and viral load.
• Assessed T cell apoptosis (spontaneous and Fas-mediated) and wasting syndrome incidence.

Main Results:

• rIL-2 induced dose-dependent expansion of CD4+ and CD8+ T cells, including regulatory T cells (Tregs).
• Higher rIL-2 doses significantly increased CD4+ and CD8+ T cell apoptosis.
• All rIL-2 treated macaques developed wasting syndrome and decreased effector T cells post-treatment.

Conclusions:

• IL-2's effects on T cell homeostasis are dose-dependent in SIV infection.
• High-dose IL-2 can promote T cell apoptosis and adverse effects like wasting syndrome.
• Findings contribute to understanding IL-2's complex role in SIV/HIV infection management.